R. Gerth van Wijk
Erasmus University Rotterdam
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by R. Gerth van Wijk.
Allergy | 2008
Jean Bousquet; N. Khaltaev; A. A. Cruz; J. Denburg; W. J. Fokkens; A. Togias; T. Zuberbier; Carlos E. Baena-Cagnani; G. W. Canonica; C. van Weel; Ioana Agache; N. Aït-Khaled; C. Bachert; M. S. Blaiss; S. Bonini; Louis Philippe Boulet; P. J. Bousquet; P. Camargos; K.-H. Carlsen; Y. Chen; Adnan Custovic; Ronald Dahl; P. Demoly; H. Douagui; Stephen R. Durham; R. Gerth van Wijk; O. Kalayci; M. A. Kaliner; Y. Y. Kim; M. L. Kowalski
J. Bousquet, N. Khaltaev, A. A. Cruz, J. Denburg, W. J. Fokkens, A. Togias, T. Zuberbier, C. E. Baena-Cagnani, G. W. Canonica, C. van Weel, I. Agache, N. A t-Khaled, C. Bachert, M. S. Blaiss, S. Bonini, L.-P. Boulet, P.-J. Bousquet, P. Camargos, K.-H. Carlsen, Y. Chen, A. Custovic, R. Dahl, P. Demoly, H. Douagui, S. R. Durham, R. Gerth van Wijk, O. Kalayci, M. A. Kaliner, Y.-Y. Kim, M. L. Kowalski, P. Kuna, L. T. T. Le, C. Lemiere, J. Li, R. F. Lockey, S. Mavale-Manuel , E. O. Meltzer, Y. Mohammad, J. Mullol, R. Naclerio, R. E. O Hehir, K. Ohta, S. Ouedraogo, S. Palkonen, N. Papadopoulos, G. Passalacqua, R. Pawankar, T. A. Popov, K. F. Rabe, J. Rosado-Pinto, G. K. Scadding, F. E. R. Simons, E. Toskala, E. Valovirta, P. van Cauwenberge, D.-Y. Wang, M. Wickman, B. P. Yawn, A. Yorgancioglu, O. M. Yusuf, H. Zar Review Group: I. Annesi-Maesano, E. D. Bateman, A. Ben Kheder, D. A. Boakye, J. Bouchard, P. Burney, W. W. Busse, M. Chan-Yeung, N. H. Chavannes, A. Chuchalin, W. K. Dolen, R. Emuzyte, L. Grouse, M. Humbert, C. Jackson, S. L. Johnston, P. K. Keith, J. P. Kemp, J.-M. Klossek, D. Larenas-Linnemann, B. Lipworth, J.-L. Malo, G. D. Marshall, C. Naspitz, K. Nekam, B. Niggemann, E. Nizankowska-Mogilnicka, Y. Okamoto, M. P. Orru, P. Potter, D. Price, S. W. Stoloff, O. Vandenplas, G. Viegi, D. Williams
Allergy | 2008
Jean Bousquet; N. Khaltaev; Alvaro A. Cruz; Judah A. Denburg; W. J. Fokkens; Alkis Togias; T. Zuberbier; Carlos E. Baena-Cagnani; G. W. Canonica; C. van Weel; Ioana Agache; N. Aït-Khaled; Claus Bachert; Michael S. Blaiss; Sergio Bonini; Louis-Philippe Boulet; P.-J. Bousquet; Paulo Augusto Moreira Camargos; K.-H. Carlsen; Yijing Chen; Adnan Custovic; Ronald Dahl; P. Demoly; H. Douagui; Stephen R. Durham; R. Gerth van Wijk; O. Kalayci; Michael Kaliner; Y.‐Y. Kim; M. L. Kowalski
J. Bousquet, N. Khaltaev, A. A. Cruz, J. Denburg, W. J. Fokkens, A. Togias, T. Zuberbier, C. E. Baena-Cagnani, G. W. Canonica, C. van Weel, I. Agache, N. A t-Khaled, C. Bachert, M. S. Blaiss, S. Bonini, L.-P. Boulet, P.-J. Bousquet, P. Camargos, K.-H. Carlsen, Y. Chen, A. Custovic, R. Dahl, P. Demoly, H. Douagui, S. R. Durham, R. Gerth van Wijk, O. Kalayci, M. A. Kaliner, Y.-Y. Kim, M. L. Kowalski, P. Kuna, L. T. T. Le, C. Lemiere, J. Li, R. F. Lockey, S. Mavale-Manuel , E. O. Meltzer, Y. Mohammad, J. Mullol, R. Naclerio, R. E. O Hehir, K. Ohta, S. Ouedraogo, S. Palkonen, N. Papadopoulos, G. Passalacqua, R. Pawankar, T. A. Popov, K. F. Rabe, J. Rosado-Pinto, G. K. Scadding, F. E. R. Simons, E. Toskala, E. Valovirta, P. van Cauwenberge, D.-Y. Wang, M. Wickman, B. P. Yawn, A. Yorgancioglu, O. M. Yusuf, H. Zar Review Group: I. Annesi-Maesano, E. D. Bateman, A. Ben Kheder, D. A. Boakye, J. Bouchard, P. Burney, W. W. Busse, M. Chan-Yeung, N. H. Chavannes, A. Chuchalin, W. K. Dolen, R. Emuzyte, L. Grouse, M. Humbert, C. Jackson, S. L. Johnston, P. K. Keith, J. P. Kemp, J.-M. Klossek, D. Larenas-Linnemann, B. Lipworth, J.-L. Malo, G. D. Marshall, C. Naspitz, K. Nekam, B. Niggemann, E. Nizankowska-Mogilnicka, Y. Okamoto, M. P. Orru, P. Potter, D. Price, S. W. Stoloff, O. Vandenplas, G. Viegi, D. Williams
Allergy | 2014
Oliver Pfaar; P. Demoly; R. Gerth van Wijk; Sergio Bonini; Jean Bousquet; G. W. Canonica; Stephen R. Durham; Lars Jacobsen; H.-J. Malling; Ralph Mösges; Nikolaos G. Papadopoulos; Sabina Rak; P. Rodriguez del Rio; E. Valovirta; Ulrich Wahn; Moises A. Calderon
BACKGROUND Allergen immunotherapy (AIT) has been thoroughly documented in randomized controlled trials (RCTs). It is the only immune-modifying and causal treatment available for patients suffering from IgE-mediated diseases such as allergic rhinoconjunctivitis, allergic asthma and insect sting allergy. However, there is a high degree of clinical and methodological heterogeneity among the endpoints in clinical studies on AIT, for both subcutaneous and sublingual immunotherapy (SCIT and SLIT). At present, there are no commonly accepted standards for defining the optimal outcome parameters to be used for both primary and secondary endpoints. METHODS As elaborated by a Task Force (TF) of the European Academy of Allergy and Clinical Immunology (EAACI) Immunotherapy Interest Group, this Position Paper evaluates the currently used outcome parameters in different RCTs and also aims to provide recommendations for the optimal endpoints in future AIT trials for allergic rhinoconjunctivitis. RESULTS Based on a thorough literature review, the TF members have outlined recommendations for nine domains of clinical outcome measures. As the primary outcome, the TF recommends a homogeneous combined symptom and medication score (CSMS) as a simple and standardized method that balances both symptoms and the need for antiallergic medication in an equally weighted manner. All outcomes, grouped into nine domains, are reviewed. CONCLUSION A standardized and globally harmonized method for analysing the clinical efficacy of AIT products in RCTs is required. The EAACI TF highlights the CSMS as the primary endpoint for future RCTs in AIT for allergic rhinoconjunctivitis.
Allergy | 2010
Santiago Quirce; Catherine Lemière; F. de Blay; V. del Pozo; R. Gerth van Wijk; Piero Maestrelli; G. Pauli; P. Pignatti; Monika Raulf-Heimsoth; J. Sastre; T. Storaas; Gianna Moscato
To cite this article: Quirce S, Lemière C, de Blay F, del Pozo V, Gerth Van Wijk R, Maestrelli P, Pauli G, Pignatti P, Raulf‐Heimsoth M, Sastre J, Storaas T, Moscato G. Noninvasive methods for assessment of airway inflammation in occupational settings. Allergy 2010; 65: 445–458.
Clinical & Experimental Allergy | 1997
H. M. Blom; J. B. Rijswuk; Ingrid M. Garrelds; Paul G.H. Mulder; T. Timmermans; R. Gerth van Wijk
Background Several authors described capsaicin, the pungent substance in red pepper, as an efficacious therapy for non‐allergic non‐infectious perennial rhinitis (NANIPER). Repeated capsaicin application induces peptide depletion and specific degeneration of the unmyelinated sensory C‐fibres in the nasal mucosa.
Pediatric Allergy and Immunology | 2012
Moises A. Calderon; R. Gerth van Wijk; I Eichler; Paolo Maria Matricardi; Eva-Maria Varga; Matthias V. Kopp; Peter Eng; B. Niggemann; Antonio Nieto; E. Valovirta; Philippe Eigenmann; Giovanni B. Pajno; Albrecht Bufe; Susanne Halken; Kirsten Beyer; Ulrich Wahn
To cite this article: Calderon MA, Gerth van Wijk R, Eichler I, Matricardi PM, Varga EM, Kopp MV, Eng P, Niggemann B, Nieto A, Valovirta E, Eigenmann PA, Pajno G, Bufe A, Halken S, Beyer K, Wahn U. Perspectives on allergen‐specific immunotherapy in childhood: An EAACI position statement. Pediatr Allergy Immunol 2012: 23: 300–306.
Allergy | 2011
Jean Bousquet; H. J. Schünemann; P. J. Bousquet; Claus Bachert; G. W. Canonica; Thomas B. Casale; P Demoly; Stephen R. Durham; K-H. Carlsen; H.-J. Malling; G. Passalacqua; F.E.R. Simons; J. M. Anto; Carlos E. Baena-Cagnani; K. C. Bergmann; T. Bieber; Andrew Briggs; Jan Brozek; Moises A. Calderon; Ronald Dahl; Philippe Devillier; R. Gerth van Wijk; Peter H. Howarth; Désirée Larenas; Nikolaos G. Papadopoulos; Peter Schmid-Grendelmeier; Torsten Zuberbier
To cite this article: Bousquet J, Schünemann HJ, Bousquet PJ, Bachert C, Canonica GW, Casale TB, Demoly P, Durham S, Carlsen K‐H, Malling H‐J, Passalacqua G, Simons FER, Anto J, Baena‐Cagnani CE, Bergmann K‐C, Bieber T, Briggs AH, Brozek J, Calderon MA, Dahl R, Devillier P, Gerth van Wijk R, Howarth P, Larenas D, Papadopoulos NG, Schmid‐Grendelmeier P, Zuberbier T. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA‐GA2LEN statement. Allergy 2011; 66: 765–774.
Allergy | 2010
S.G.O. Johansson; E. Florvaag; H. Öman; Lars K. Poulsen; Paul-Michel Mertes; N. J. N. Harper; L. H. Garvey; R. Gerth van Wijk; T. Metso; Å. Irgens; T. Dybendal; J. Halsey; S. L. Seneviratne; Anne Berit Guttormsen
To cite this article: Johansson SGO, Florvaag E, Öman H, Poulsen LK, Mertes PM, Harper NJN, Garvey LH, Gerth van Wijk R, Metso T, Irgens A, Dybendal T, Halsey J, Seneviratne SL, Guttormsen AB. National pholcodine consumption and prevalence of IgE‐sensitization: a multicentre study. Allergy 2010; 65: 498–502.
Allergy | 2015
Constantinos Pitsios; Pascal Demoly; Maria Beatrice Bilò; R. Gerth van Wijk; Oliver Pfaar; Gunter J. Sturm; P. Rodriguez del Rio; M. Tsoumani; Radoslaw Gawlik; Giannis Paraskevopoulos; Franziska Ruëff; E. Valovirta; Nikolaos G. Papadopoulos; Moises A. Calderon
Clinical indications for allergen immunotherapy (AIT) in respiratory and Hymenoptera venom allergy are well established; however, clinical contraindications to AIT are not always well documented. There are some discrepancies when classifying clinical contraindications for different forms of AIT as ‘absolute’ or ‘relative’. EAACI Task Force on ‘Contraindications to AIT’ was created to evaluate and review current literature on clinical contraindications, and to update recommendations for both sublingual and subcutaneous AIT for respiratory and venom immunotherapy. An extensive review of the literature was performed on the use of AIT in asthma, autoimmune disorders, malignant neoplasias, cardiovascular diseases, acquired immunodeficiencies and other chronic diseases (including mental disorders), in patients treated with β‐blockers, ACE inhibitors or monoamine oxidase inhibitors, in children under 5 years of age, during pregnancy and in patients with poor compliance. Each topic was addressed by the following three questions: (1) Are there any negative effects of AIT on this concomitant condition/disease? (2) Are more frequent or more severe AIT‐related side‐effects expected? and (3) Is AIT expected to be less efficacious? The evidence, for the evaluation of these clinical conditions as contraindications, was limited, and most of the conclusions were based on case reports. Based on an extended literature research, recommendations for each medical condition assessed are provided. The final decision on the administration of AIT should be based on individual evaluation of any medical condition and a risk/benefit assessment for each patient.
Allergy | 2010
Fulvio Braido; P. J. Bousquet; Z. Brzoza; G. W. Canonica; Enrico Compalati; Alessandro Fiocchi; W. J. Fokkens; R. Gerth van Wijk; S. La Grutta; Carlo Lombardi; M. Maurer; Anabela Mota Pinto; Erminia Ridolo; G. Senna; I. Terreehorst; A. Todo Bom; Jean Bousquet; T. Zuberbier; Ilaria Baiardini
To cite this article: Braido F, Bousquet PJ, Brzoza Z, Canonica GW, Compalati E, Fiocchi A, Fokkens W, Gerth van Wijk R, La Grutta S, Lombardi C, Maurer M, Pinto AM, Ridolo E, Senna GE, Terreehorst I, Todo Bom A, Bousquet J, Zuberbier T, Baiardini I. Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA2LEN taskforce position paper. Allergy 2010; 65: 959–968.